British Pharmacopoeia

The British Pharmacopoeia (BP) is the United Kingdom's national pharmacopoeia: an annually updated collection of public standards used to define and assess the quality of medicinal substances, excipients, formulated preparations and selected related products. It is not a catalogue of treatments and does not, by itself, establish that a substance is safe or effective for a particular disease. Instead, its standards provide an independent basis for judging identity, purity, strength and other quality characteristics throughout a medicine's shelf life. The BP forms part of the United Kingdom's statutory medicines-control framework. It is published on behalf of the UK Health Ministers under the Medicines Act 1968, on the recommendation of the Commission on Human Medicines. The British Pharmacopoeia Commission is responsible for preparing and maintaining the publication, continuing work that originated with earlier national pharmacopoeial commissions. The compendium complements licensing, inspection and regulatory activity conducted by the Medicines and Healthcare products Regulatory Agency (MHRA). Together with the British National Formulary, it is one of the principal reference points for medicines practice in the United Kingdom, although the BP is concerned primarily with quality standards rather than prescribing guidance. The modern BP emerged from the consolidation of the London, Edinburgh and Dublin pharmacopoeias. Its first edition was published in 1864, making it one of the earliest national attempts to harmonise pharmaceutical standards across the United Kingdom. The historical development of national standards followed earlier efforts to control medicines, including the London Pharmacopoeia of 1618 and statutory responsibilities assigned to the General Medical Council in the nineteenth century. The Medicines Act 1968 subsequently gave the British Pharmacopoeia Commission and the BP a specific legal foundation. The publication has developed into a substantial reference system. Its contents include monographs for medicinal substances, excipients and formulated preparations, together with general notices, analytical appendices, reagents, test methods, reference spectra and indexes. Separate or associated material covers blood-related preparations, immunological products, radiopharmaceutical preparations, surgical materials and homeopathic preparations. Veterinary products used exclusively in the United Kingdom are covered in the British Pharmacopoeia (Veterinary). The BP is available in print and electronic forms, including online and CD-ROM formats, with extensive internal linking designed to connect monographs, appendices and related reference information. The production system combines policy, scientific review and laboratory work. The Pharmacopoeial Secretariat works with the British Pharmacopoeia Commission, the British Pharmacopoeia Laboratory, expert advisory groups and advisory panels. Contributions can come from pharmaceutical manufacturers, hospitals, universities, professional organisations and government bodies in the United Kingdom and abroad. The laboratory develops and validates analytical methods for new and existing monographs and maintains British Pharmacopoeia Chemical Reference Substances (BPCRS), which are used as comparison standards in pharmacopoeial testing. The BP also supports the naming of medicines through British Approved Names (BANs). These are concise, non-proprietary names selected or devised by the British Pharmacopoeia Commission and published by the Health Ministers on the recommendation of the Commission on Human Medicines. Since 2002, subject to stated exceptions, BANs may be treated as recommended International Nonproprietary Names under the relevant European medicines framework. Through its standards, reference materials and nomenclature work, the British Pharmacopoeia serves regulators, manufacturers, researchers, laboratories, pharmacists and other organisations involved in pharmaceutical development, production and quality control. Its influence extends beyond Britain: some countries have adopted it as a national standard, while others recognise it as an acceptable reference pharmacopoeia.

The British Pharmacopoeia belongs to a long tradition of official attempts to control the quality of medicines in Britain. During the reign of Henry VIII, the Royal College of Physicians of London had authority to inspect apothecaries' products in the London area and destroy defective stock. The London Pharmacopoeia, published in 1618, provided an early list of approved drugs and instructions for their preparation. Growing concern about inconsistent and potentially dangerous medicines led to calls for a unified national reference. In 1844, William Flockhart, who had supplied chloroform for James Young Simpson's anaesthesia experiments, advocated the creation of a universal pharmacopoeia for Great Britain in an address associated with the Northern British branch of the Pharmaceutical Society. The General Medical Council later received a statutory role under the Medical Act 1858 in producing a national British pharmacopoeia. This responsibility led to the appointment of a commission and the work that culminated in the first British Pharmacopoeia. Published in 1864, that edition brought together traditions represented by the London, Edinburgh and Dublin pharmacopoeias. The consolidation was an important step toward common pharmaceutical standards across the United Kingdom. The Latinised title Pharmacopoeia Britannica, abbreviated Ph. Br., was also used historically. In 1907, the British Pharmacopoeia was supplemented by the British Pharmaceutical Codex, which supplied information about substances not included in the BP and provided additional standards. The legal and institutional position of the BP was significantly clarified by the Medicines Act 1968. The Act established the statutory status of the British Pharmacopoeia Commission and recognised the BP as the United Kingdom standard for medicinal products. The Commission retained responsibility for preparing new editions, updating existing standards and producing the veterinary pharmacopoeia. It also received responsibility under section 100 of the Medicines Act for selecting and devising British Approved Names. Over time, the BP expanded from a printed national book into a broader technical reference system. Its monographs cover active medicinal substances, excipients and formulated preparations, while its supporting material includes general notices, analytical procedures, reagents, reference spectra and comprehensive indexes. European Pharmacopoeia monographs, including amendments issued through Council of Europe supplements, are reproduced in the BP or in the associated veterinary edition. The publication is also distributed electronically, with online and CD-ROM products providing search functions and links among related entries. Preparation of the BP is carried out through cooperation among the Pharmacopoeial Secretariat, the British Pharmacopoeia Commission, the British Pharmacopoeia Laboratory and specialist advisory groups. Scientific input is obtained from industry, hospitals, academic institutions, professional bodies and government sources. The laboratory develops and validates methods for new monographs, reviews existing methods and manages British Pharmacopoeia Chemical Reference Substances used in analytical testing. The BP's reach has become international. Since its first publication, it has been distributed outside the United Kingdom and is now used in more than 100 countries. Australia and Canada are identified as countries that have adopted it as a national standard, while South Korea is among countries recognising it as an acceptable reference standard. Its role remains complementary to medicines licensing and inspection: compliance with a monograph supports a judgement about product quality, but inclusion of a substance does not represent an endorsement of its therapeutic safety or efficacy.

• 2002

  British Approved Names aligned with international naming practice

  [1]British Pharmacopoeiaen.wikipedia.org

  Following the relevant European medicines directive, British Approved Names could generally be treated as recommended International Nonproprietary Names, subject to exceptions.

• 1968

  Medicines Act gives the BP statutory status

  [1]British Pharmacopoeiaen.wikipedia.org

  The Medicines Act established the legal status of the British Pharmacopoeia Commission and the BP as the United Kingdom standard for medicinal products.

• 1907

  British Pharmaceutical Codex introduced

  [1]British Pharmacopoeiaen.wikipedia.org

  The British Pharmaceutical Codex supplemented the BP with information and standards for additional pharmaceutical substances.

• 1864

  First British Pharmacopoeia edition

  [1]British Pharmacopoeiaen.wikipedia.org

  The first edition of the British Pharmacopoeia was published, combining the London, Edinburgh and Dublin pharmacopoeial traditions.

• 1858

  National pharmacopoeial responsibility established

  [1]British Pharmacopoeiaen.wikipedia.org

  The Medical Act made the General Medical Council statutorily responsible for producing a British pharmacopoeia on a national basis.

• 1844

  Call for a universal British pharmacopoeia

  [1]British Pharmacopoeiaen.wikipedia.org

  William Flockhart publicly supported the creation of a unified pharmacopoeia for Great Britain in response to concerns about unregulated pharmaceutical manufacture and use.

• 1618

  London Pharmacopoeia published

  [1]British Pharmacopoeiaen.wikipedia.org

  The London Pharmacopoeia provided an early official list of drugs and preparation instructions, forming part of the historical foundation for later British national standards.

An official, standards-based pharmaceutical reference and regulatory-quality resource for the United Kingdom, combining legally enforceable monographs with analytical methods, reference materials and medicine nomenclature.

• Pharmaceutical standards compendium · 1864

  British Pharmacopoeia

  The principal annual compendium of United Kingdom pharmaceutical quality standards. It contains monographs for medicinal substances, excipients and formulated preparations, supported by general notices, analytical methods, appendices, reagents, reference spectra and indexes. It is distributed in print and electronic formats and is used by regulators, manufacturers, laboratories, researchers, pharmacists and other organisations involved in medicines quality control.

• Veterinary pharmaceutical standards

  British Pharmacopoeia (Veterinary)

  The veterinary counterpart to the BP, covering products and standards relevant to veterinary medicines, including items used exclusively in veterinary medicine in the United Kingdom. It is prepared and maintained within the British pharmacopoeial system and is distributed as associated reference material.

• Analytical reference materials

  British Pharmacopoeia Chemical Reference Substances

  Reference substances maintained by the British Pharmacopoeia Laboratory for use in tests specified by BP and BP (Veterinary) monographs. The laboratory is responsible for their procurement, establishment, maintenance and sale, supporting laboratories that need controlled comparison materials for pharmaceutical analysis.

• Non-proprietary medicine nomenclature

  British Approved Names

  Short, distinctive non-proprietary names for pharmaceutical substances or articles whose systematic chemical or scientific names may be inconvenient for general use. They are selected or devised by the British Pharmacopoeia Commission and published by the UK Health Ministers on the recommendation of the Commission on Human Medicines.

• 2002

  Alignment of British Approved Names with international nomenclatureStrategy

  Background

  European medicines legislation affected the relationship between national medicine names and World Health Organization International Nonproprietary Names.

  Action taken

  British Approved Names were generally permitted to serve as recommended International Nonproprietary Names, except where specific exceptions applied.

  Aftermath

  The naming system became more closely aligned with internationally recognised generic naming practice.

  Source

• 1968

  Statutory integration into medicines regulationStrategy

  Background

  The United Kingdom required a legally defined national standard to support consistent assessment of medicinal-product quality alongside licensing and inspection.

  Action taken

  The Medicines Act 1968 established the legal status of the British Pharmacopoeia Commission and recognised the British Pharmacopoeia as the UK standard for medicinal products.

  Aftermath

  The BP became a formal component of the United Kingdom's medicines-control framework, with the Commission responsible for preparing editions and maintaining standards.

  Source

1. 1British Pharmacopoeiaen.wikipedia.org
2. 2British Pharmacopoeia official websitepharmacopoeia.co.uk